# Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

> **NCT05990231** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 35 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cadonilimab combined Anlotinib

## Key facts

- **NCT ID:** NCT05990231
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05990231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05990231, "Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05990231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*